Table 2. Cox Regression Univariable and Multivariable Analysis of Disease-Specific Survival in the Entire Cohort and Within Low-Grade EC.
| Variable | Entire cohort | Low-grade EC | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariable DSS | Multivariable DSS, 73 events | Univariable DSS | Multivariable DSS, 12 events | |||||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |||
| Patient age (continuous) | 1.04 (1.02-1.07) | .001 | 1.02 (0.99-1.05) | .08 | NAa | NAa | NAa | NAa | ||
| Grade | ||||||||||
| 1-2 | 1 [Reference] | <.001 | 1 [Reference] | <.001 | NAa | NAa | NAa | NAa | ||
| 3 | 7.70 (4.13-14.35) | 4.29 (2.15-8.53) | NAa | NAa | ||||||
| Molecular subgroup | ||||||||||
| POLE-alt | 0.17 (0.02-1.27) | .09 | 0.16 (0.02-1.16) | .07 | 0.00 (0.00-0.00) | .99 | 0.00 (0.00-0.00) | .98 | ||
| MSI | 0.45 (0.19-1.11) | .08 | 0.51 (0.21-1.22) | .13 | 0.73 (0.15-3.40) | .69 | 0.65 (0.13-3.02) | .58 | ||
| TP53-alt | 4.14 (2.53-6.75) | <.001 | 1.76 (1.04-2.95) | .03 | 1.58 (0.19-12.63) | .66 | 2.94 (0.33-25.83) | .63 | ||
| NSMP | 1 [Reference] | NA | 1 [Reference] | NA | 1 [Reference] | NA | 1 [Reference] | NA | ||
| LVSI | ||||||||||
| No | 1 [Reference]] | <.001 | 1 [Reference] | .64 | 1 [Reference] | .30 | 1 [Reference] | .78 | ||
| Yes | 3.78 (2.37-6.00) | 1.13 (0.67-1.88) | 2.27 (0.48-10.57) | 1.28 (0.24-6.88) | ||||||
| FIGO | ||||||||||
| Stage I-II | 1 [Reference] | <.001 | 1 [Reference] | <.001 | 1 [Reference] | .01 | 1 [Reference] | .008 | ||
| Stage III-IV | 7.02 (4.35-11.33) | 4.26 (2.50-7.26) | 4.57 (1.43-14.56) | 5.38 (1.55-18.62) | ||||||
Abbreviations: alt, altered; EC, endometrial cancer; FIGO, Federation International of Gynecology and Obstetrics; HR, hazard ratio; LVSI, lymphovascular space invasion; MSI, microsatellite instability; NA, not applicable; NSMP, no specific molecular profile.
a
Cox regression analysis within patients with low-grade EC did not include age and grade as variables.